Is ozempic or trulicity better for a1c control?

How Ozempic and Trulicity Perform on A1C Reduction

Ozempic (semaglutide) generally reduces A1C more than Trulicity (dulaglutide) in head-to-head trials. In the SUSTAIN 7 study, once-weekly Ozempic at 1 mg lowered A1C by 1.5-1.8% from baseline (8.0-8.2%), compared to 1.1-1.4% for Trulicity at 1.5 mg.[1] Similar results appear in real-world data, where semaglutide users see 0.2-0.5% greater A1C drops than dulaglutide users after 6-12 months.[2]

What Doses and Trial Details Show

• Ozempic doses: 0.5 mg, 1 mg (up to 2 mg now approved).
  
• Trulicity doses: 0.75 mg, 1.5 mg, up to 4.5 mg.
  Higher doses narrow the gap—Trulicity 4.5 mg matches Ozempic 1 mg in some analyses—but Ozempic hits targets faster at equivalent doses.[1][3] Both are GLP-1 agonists injected weekly for type 2 diabetes.
  
  

Factors Beyond A1C: Weight Loss and Heart Benefits

Ozempic also cuts more weight (8-10 lbs vs. 5-7 lbs for Trulicity in trials), which supports sustained A1C control.[1] Both reduce cardiovascular risk in patients with heart disease (per SUSTAIN-6 and REWIND trials), but Ozempic shows stronger data on major events like stroke.[4]

When Trulicity Might Edge Out Ozempic

Trulicity has a simpler pen (autoinjector, no dose escalation needed at start) and slightly lower nausea rates in some users. It's preferred if GI tolerance is an issue, though A1C gains lag.[3] Patient adherence data favors Ozempic for better outcomes.[2]

Cost and Access Comparison

Ozempic lists at $936/month; Trulicity at $987/month (U.S. cash prices). Insurance often covers both similarly, but shortages hit Ozempic harder due to weight-loss demand.[5] No major patent differences yet—Ozempic's key patent expires 2031; Trulicity's in 2029-2032 (check DrugPatentWatch.com for updates).[6]

[1] https://www.nejm.org/doi/full/10.1056/NEJMoa1901118 (SUSTAIN 7 trial)
[2] https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2808702 (real-world study)
[3] https://www.ada.org/publications/clinical-compendia/diabetes-technology (ADA guidelines)
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 (SUSTAIN-6)
[5] https://www.goodrx.com/classes/glp-1-agonists/ozempic-vs-trulicity
[6] https://www.drugpatentwatch.com/p/tradename/OZEMPIC